News from the AGA

New AGA podcast series explores the latest in C. difficile


 

As one of the most commonly reported bacterial infections, staying up to date on the latest in Clostridioides difficile is critical for providing the best possible care for your patients. AGA’s new on-demand program, “C. difficile: Preparing the Field for Change,” is a six-part podcast series that outlines effective approaches to patient-centered care that will transform your practice.

Each 30-minute episode delves into a different topic – from microbiome therapy and FMT to documenting patient history – that will help you improve patient outcomes and reduce the risk of complications.

Tune in and subscribe to our channel Inside Scope wherever you listen to podcasts (Apple or Google). To claim CME credit for listening, visit AGA University (agau.gastro.org).

Episode breakdown


Risk factors
Dr. Paul Feuerstadt and Dr. Sahil Khanna cover risk factors for initial and recurrent C. difficile infection.

Microbiota changes
Dr. Paul Feuerstadt and Dr. Sahil Khanna describe the shifts in the microbiota with C. difficile infection.

Reconciling guideline differences for testing and treatment
Dr. Paul Feuerstadt and Dr. Sahil Khanna are joined by guest Dr. Colleen Kelly to discuss how to reconcile guideline differences for testing and treatment of C. difficile.

Case management and transitions of care
Dr. Paul Feuerstadt and Dr. Sahil Khanna are joined by guests Rebecca Perez and Cheri Lattimer to discuss case management and transitions of care in C. difficile infection.

Impact of rCDI on patients and their lives
Dr. Paul Feuerstadt and Dr. Sahil Khanna are joined by guests Dr. Kevin Garey and Melissa Passarello to discuss the impact of recurrent CDI on patients and their lives. 

FMT and new microbiome therapies
Dr. Paul Feuerstadt and Dr. Sahil Khanna are joined by guest Dr. Jessica Allegretti to discuss FMT and new microbiome therapies.

This series is supported by educational grants from Aimmune Therapeutics, Seres Therapeutics, and Ferring Pharmaceuticals. 

Next Article: